Craft

Oxford BioTherapeutics

Total Funding

$21.6 M

Revenue

£2.1 M

FY, 2018

Oxford BioTherapeutics Summary

Company Summary

Overview
Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.
Type
Private
Status
Active
Founded
2004
HQ
Milton, GB | view all locations
Website
http://www.oxfordbiotherapeutics.com/
Cybersecurity rating
Sectors

Key People

  • Jean-Pierre Bizzari

    Jean-Pierre Bizzari, Non-Executive Director

    • Fiona Irvine

      Fiona Irvine, Vp & Head of Human Resources

      • Abderrahim Fandi

        Abderrahim Fandi, Chief Medical Officer

        • Ken Sayre, Vp Finance & Us Operations

          LocationsView all

          2 locations detected

          • Milton, England HQ

            United Kingdom

            94a Innovation Dr

          • San Jose, CA

            United States

            5941 Optical Ct

          Oxford BioTherapeutics Financials

          Summary Financials

          Revenue (FY, 2018)
          £2.1M
          Net income (FY, 2018)
          (£6.5M)
          Cash (FY, 2018)
          £3.6M
          EBIT (FY, 2018)
          (£6.5M)

          Footer menu